Charts

Sentiment shifts periodically on Wall Street, and you could argue Cathie Wood might be the prime example of fortune reversal. Once an investor favorite and hailed as a pioneer with a portfolio jam-packed with the novel and cutting-edge, Wood’s reputation has been tarnished over the past year and a half as her growth-oriented investing style went out of fashion in the post-pandemic climate. Does that mean Wood is ready to desert her strategy of backing innovative yet risky and often unprofitable

The popular growth investor publishes her daily transactions. Cathie Wood keeps buying Tesla as well as some of her smaller holdings.

Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of ...

In trading on Wednesday, the Copper Miners ETF is outperforming other ETFs, up about 4% on the day. Components of that ETF showing particular strength include shares of Lundin Mining, up about 6.8% and shares of Hudbay Minerals, up about 6.2% on the day.

Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2022.

The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that...

Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 28, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Health Care Equipment ETF (XHE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $116.76 per unit.

Cerus Corporation (Nasdaq: CERS) announced today that the Company will participate in two upcoming investor conferences.

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 150 points on Monday. The Dow traded ...

Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company ...

Gainers CinCor Pharma (NASDAQ:CINC) shares increased by 148.0% to $29.22 during Monday's regular session. As of 12:30 EST, CinCor ...

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Monday. The Dow traded up ...

Companies That Fell Through 52-Week Lows Monday During Monday's morning trading, 14 companies set new 52-week lows. Things to ...

Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2022 and provided product revenue guidance for full-year 2023.

Every investor in Cerus Corporation ( NASDAQ:CERS ) should be aware of the most powerful shareholder groups. We can see...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Health Care Equipment ETF (XHE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $112.33 per unit.

Benzinga Pro data, Cerus (NASDAQ:CERS) reported Q3 sales of $39.57 million. Earnings fell to a loss of $8.52 million, resulting in a ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Health Care Equipment ETF (XHE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $114.64 per unit.

Cerus ( NASDAQ:CERS ) Third Quarter 2022 Results Key Financial Results Revenue: US$39.6m (up 9.5% from 3Q 2021). Net...

Cerus (CERS) delivered earnings and revenue surprises of 0% and 1.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2022.

Cerus Corporation (Nasdaq: CERS) today announced that it has been awarded a $9.1 million contract by the U.S. Department of Defense (DoD) Industrial Base Analysis and Sustainment (IBAS) program for the development of pathogen reduced, lyophilized cryoprecipitate (“LyoCryo”) to treat bleeding due to trauma.

Cerus Corporation (Nasdaq:CERS) today announced it has received approval from Health Canada to extend the storage of platelets treated with the INTERCEPT Blood System from five days to seven days from the time of collection, joining other territories where INTERCEPT platelets are approved for seven-day storage.

Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2022 financial results will be released on Thursday, November 3, 2022, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2022 AABB Annual Meeting, taking place in Orlando, FL from October 1 through October 4. This year’s AABB Annual Meeting attracts individuals and institutions from around the globe involved in the fields of transfusion medicine and biotherapies. This year marks the first time the conference has taken place in person since 2019, as well as its 75th anniversary.

Cerus (CERS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

It might be of some concern to shareholders to see the Cerus Corporation ( NASDAQ:CERS ) share price down 24% in the...

Zimmer (ZBH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Cerus (CERS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Health Care Equipment ETF (XHE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $124.47 per unit.

This billionaire-guided hedge fund went bargain-shopping in the second quarter.

Cerus Corporation (Nasdaq: CERS) acknowledges the U.S. Department of Health and Human Services’ declaration of monkeypox as a national Public Health Emergency. Currently, more than 10,000 cases of monkeypox have been reported across the U.S., and over 30,000 cases have been confirmed globally.

CERS earnings call for the period ending June 30, 2022.

Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2022.

In trading on Wednesday, shares of Cerus Corp. (CERS) crossed above their 200 day moving average of $5.73, changing hands as high as $5.76 per share..

Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2022 financial results will be released on Thursday, August 4, 2022, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

They are also outperforming the S&P 500.

Cerus Corporation (Nasdaq: CERS) today announced the appointment of Hua Shan, MD, PhD, Professor of Pathology and Medical Director, Transfusion Medicine Service at Stanford Medical Center to its Board of Directors.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Health Care Equipment ETF (XHE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $132.48 per unit.

Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2022.

Delivering on a promise is a tough proposition, and to consistently deliver requires excellence on all fronts. When companies offer ...

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Health Care Equipment ETF (XHE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $141.18 per unit.

CERS earnings call for the period ending March 31, 2022.

Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2022.

Cerus Corporation (Nasdaq: CERS) today announced that it has signed a ten-year agreement with Fresenius Kabi for the production of INTERCEPT Blood System sets. This new contract replaces the current one with Fresenius Kabi that was set to expire in July 2025.

In trading on Monday, the ARK Innovation ETF is outperforming other ETFs, up about 2.9% on the day. Components of that ETF showing particular strength include shares of Ginkgo Bioworks Holdings, up about 9% and shares of Cerus, up about 7% on the day.

Cerus Corporation (Nasdaq: CERS) today announced that it has signed a five-year contract with the American Red Cross for the INTERCEPT Blood System for Platelets.

Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2022 financial results will be released on Thursday, May 5, 2022, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

Cerus Corporation (Nasdaq: CERS) today announced that Kevin D. Green, Cerus’ chief financial officer, is scheduled to participate at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 1:30 p.m. EST.

Cerus Corp's(NASDAQ: CERS)Q4 FY21 product revenue was $39.9 million, compared to $28.2 million, driven by increased ...

CERS earnings call for the period ending December 31, 2021.

Cerus (NASDAQ:CERS) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM. Here's what investors need to ...

Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2021.

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— SSGA US Small Cap Low Volatility Index ETF (SMLV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $130.84 per unit.

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per ...